Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Pre-Mkt 12-18 07:51:53 EST

19.25

+0.43

+2.28%

High20.20	Low18.90	Vol329.86K
Open19.00	D1 Closing18.82	Amplitude6.91%
Mkt Cap349.08M	Tradable Cap223.34M	Total Shares18.13M
T/O6.41M	T/O Rate2.84%	Tradable Shares11.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":19.25,"timestamp":1766005200000,"preClose":18.82,"halted":0,"volume":329859,"delay":0,"floatShares":11601900,"shares":18133968,"eps":-8.742119,"marketStatus":"Pre-Mkt","change":0.43,"latestTime":"12-18 07:51:53 EST","open":19,"high":20.2,"low":18.9,"amount":6414043.272777,"amplitude":0.069075,"askPrice":21.71,"askSize":100,"bidPrice":19.51,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-8.742119,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":19.25,"postHourTrading":{"tag":"盘后","latestPrice":19.51,"preClose":19.25,"latestTime":"19:52 EST","volume":20019,"amount":385485.0105,"timestamp":1766019128069},"volumeRatio":1.2179046486151393,"impliedVol":0.6495,"impliedVolPercentile":0.2941},"requestUrl":"/m/hq/s/AVTX/wiki","defaultTab":"wiki","newsList":[{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","AZO","IP","IE00BFSS8Q28.SGD","ELF","BRO","MU","UPB","LEN","SLVM","IE00BVYPNW00.USD","BK4191","PEN","PGR","SEE","BK4107","RYN","CL","COUR","PMT","BCAX","EW","FAF","IE00BKPKM429.USD","PFSI","SHAK","HOUS","PG","SYRE","AJG","RKT","STC","ALB","NMIH","HUT","AVTX","VTGN","UDMY","VVV","LU1559883803.SGD","LU0965509101.SGD","LU0175139822.USD","CLW","PCH","WOR","LU0081259029.USD","RVLV","INSM","PRMB","FNF"],"gpt_icon":0},{"id":"2588032991","title":"Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2588032991","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588032991?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:08","pubTimestamp":1764673713,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. presented updates on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound AVTX-009, an anti-IL-1β monoclonal antibody. AVTX-009 is positioned as a potential best-in-class therapy for hidradenitis suppurativa , addressing unmet needs in patients with incomplete or lost response to current treatments. The company noted that AVTX-009 exhibits 15 times higher affinity and a longer half-life compared to lutikizumab, which may translate to higher efficacy and less frequent dosing. Enrollment for the Phase 2 LOTUS trial in HS is complete, with topline data expected in the second quarter of 2026. The HS market is projected to grow significantly, with additional indications for AVTX-009 under consideration. Avalo stated it has sufficient cash runway into 2028. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7TL2xg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2581868717","title":"Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581868717","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581868717?lang=en_us&edition=fundamental","pubTime":"2025-11-08 21:21","pubTimestamp":1762608092,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/will-avalo-therapeutics-nasdaqavtx-spend-its-cash-wisely","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/will-avalo-therapeutics-nasdaqavtx-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NQmain","AVTX","NVIW.SI","USJW.SI","QID","SQQQ","TQQQ","MNQmain","USAW.SI","QLD","PSQ",".IXIC","TSYW.SI"],"gpt_icon":1},{"id":"2581067246","title":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067246?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:18","pubTimestamp":1762431500,"startTime":"0","endTime":"0","summary":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment completeOverviewAvalo Therapeutics Q3 net loss misses analyst expectationsOperating expenses rose due to Phase 2 LOTUS trial costsCompleted e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2581062491","title":"Avalo Therapeutics reports third quarter revenue of zero dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062491?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:02","pubTimestamp":1762430566,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. reported cash, cash equivalents, and short-term investments of $111.6 million as of September 30, 2025. Net cash used in operating activities was $37.2 million for the nine months ended September 30, 2025. The company expects its current cash resources to fund operations into 2028. Product revenue for the third quarter and nine months ended September 30, 2025, was zero, compared to $0.2 million for the same periods in 2024. Recent business developments include the completion of enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, with topline data expected in mid-2026, and the appointment of Kevin Lind to the Board of Directors, as well as new leadership in business development and human resources.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1qnlQg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","AVTX","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2581706720","title":"Avalo Therapeutics: Cash & Short-Term Investments of About $112 Mln as of Sept 30, Expected to Provide Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706720?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA997Z3M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2581438064","title":"Avalo Therapeutics Q3 Operating Expenses USD 19.198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581438064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581438064?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX39DC11:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2581064037","title":"Press Release: Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064037","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581064037?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430400,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment. -- Expanded leadership team with key appointments in business development. -- Cash and short-term investments of approximately $112 million as of. September 30, 2025 expected to provide runway into 2028. WAYNE, Pa., Nov. 06, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company fully dedicated to developing IL-1<BETA>-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the third quarter of 2025.\"Now that enrollment is complete, we're fully focused on completing the LOTUS trial, preparing for the data readout in mid-2026, and progressing our Phase 3 planning,\" said Dr. Garry Neil, Chief Executive Officer. \"This marks an important transition for Avalo as we turn our focus from enrollment to completion of the trial, guided by strong conviction in AVTX-009's high-affinity inhibition of IL-1<BETA> and its potential to deliver m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","AVTX","LENZ","BK4539"],"gpt_icon":0},{"id":"2580118972","title":"Avalo Therapeutics Inc  expected to post a loss of $1.66 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580118972","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580118972?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:19","pubTimestamp":1762179560,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc  expected to post a loss of $1.66 a share - Earnings Preview Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to  show a fall in quarterly revenue when it reports  results on N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2580305297","title":"Avalo Therapeutics to Participate in Piper Sandler Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580305297","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580305297?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171256,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. will participate in a fireside chat at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025. The company, dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, will be represented by its management team at the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2YfyVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4588","LU0314104364.USD","LU2095319765.USD","BK4139","BK4127","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4112","AVTX","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2579901358","title":"Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Anavex Life Sciences (AVXL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579901358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579901358?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:10","pubTimestamp":1761743407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avalo Therapeutics (AVTX – Research Report) and Anav...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-anavex-life-sciences-avxl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-anavex-life-sciences-avxl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX","BK4139","BK4581","XBI","HCSG","LU0128526141.USD","BK4137","BK4585","BK4588","XLV","AVXL","LU0029874061.USD","LABU"],"gpt_icon":0},{"id":"2579897410","title":"BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2579897410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579897410?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:04","pubTimestamp":1761735878,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis SuppurativaOct 29 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO THERA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA2VDXRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2579974165","title":"Avalo Therapeutics  - Lotus Trial Enrolls 250 Patients, Topline Data From Trial Is Expected in Mid-2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2579974165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579974165?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA2VDXRV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2579971791","title":"Avalo Therapeutics Announces Completion of Enrollment in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2579971791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579971791?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA2VDXRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2576303136","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576303136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576303136?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698842,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Wuxi Biologics (Cayman) (WXIBF – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-wuxi-biologics-cayman-otherwxibf-and-avalo-therapeutics-avtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-wuxi-biologics-cayman-otherwxibf-and-avalo-therapeutics-avtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242646821.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4588","LU0128526141.USD","LU0122379950.USD","SG9999001440.SGD","XBI","BK4581","HCSG","LU0868494617.USD","BK4585","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1061106388.HKD","BK4534","IE0009355771.USD","LU0058720904.USD","LU0289739699.SGD","LU2112291526.USD","BK4533","LU1983299246.USD","BK4139","IE00B4R5TH58.HKD","BK4137","LU2089984988.USD","AVTX","BK4599","AMGN","LU2468319806.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU1057294990.SGD","XLV","IE00B2B36J28.USD","LU0320765992.SGD","IE0002141913.USD","LU0029874061.USD","BK4566","LU1571399168.USD","LU0109394709.USD","LABU"],"gpt_icon":0},{"id":"2574178447","title":"Avalo Therapeutics Inc publishes presentation on advancing IL1β therapies for hidradenitis suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2574178447","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574178447?lang=en_us&edition=fundamental","pubTime":"2025-10-10 19:26","pubTimestamp":1760095574,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. provided an update on its pipeline of novel IL-1β therapies for immune-mediated inflammatory diseases, highlighting its lead compound, AVTX-009. The company emphasized AVTX-009's potential in treating hidradenitis suppurativa , a chronic inflammatory skin disease with significant unmet medical need. Data presented showed favorable efficacy in patients who had already failed anti-TNF therapy, as well as strong results in bio-nave populations. The management team, including Chief Executive Officer Garry A. Neil, MD, and Chief Medical Officer Mittie Doyle, MD, outlined progress in clinical development and the company's focus on advancing next-generation IL-1β inhibition. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5R9NW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2573983313","title":"Avalo Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Boyd Taylor","url":"https://stock-news.laohu8.com/highlight/detail?id=2573983313","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573983313?lang=en_us&edition=fundamental","pubTime":"2025-10-07 04:23","pubTimestamp":1759782206,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Boyd Taylor as the beneficial owner, serving in the role of Chief Business Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL9ybp6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2572281805","title":"Avalo Therapeutics Files Initial Beneficial Ownership Statement for Director Kevin Robert Lind","url":"https://stock-news.laohu8.com/highlight/detail?id=2572281805","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572281805?lang=en_us&edition=fundamental","pubTime":"2025-10-03 04:19","pubTimestamp":1759436370,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Kevin Robert Lind as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL6wPYgn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2572535353","title":"Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2572535353","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572535353?lang=en_us&edition=fundamental","pubTime":"2025-10-01 19:15","pubTimestamp":1759317307,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-appoints-boyd-as-cbo-ivanowicz-as-svp-human-resources-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-appoints-boyd-as-cbo-ivanowicz-as-svp-human-resources-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","AVTX"],"gpt_icon":0},{"id":"2572533144","title":"Avalo Therapeutics Announces New Inducement Compensation Plan Amid Leadership Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2572533144","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572533144?lang=en_us&edition=fundamental","pubTime":"2025-10-01 19:02","pubTimestamp":1759316533,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc. has announced new compensation terms for its recently appointed executives. Taylor Boyd, the new Chief Business Officer, has been granted 275,000 non-qualified stock options, while Ashley Ivanowicz, Senior Vice President of Human Resources, has received 100,000 non-qualified stock options. The options vest over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years. The exercise price for the options will be set at the closing price of Avalo's common stock on October 1, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electron","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL915cFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.0351},{"period":"1month","weight":0.1407},{"period":"3month","weight":0.6204},{"period":"6month","weight":3.1487},{"period":"1year","weight":1.0522},{"period":"ytd","weight":1.5908}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052653},{"month":2,"riseRate":0.4,"avgChangeRate":-0.027389},{"month":3,"riseRate":0.3,"avgChangeRate":0.322911},{"month":4,"riseRate":0.3,"avgChangeRate":-0.087519},{"month":5,"riseRate":0.3,"avgChangeRate":-0.069789},{"month":6,"riseRate":0.7,"avgChangeRate":0.011587},{"month":7,"riseRate":0.5,"avgChangeRate":0.025049},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.042687}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}